Cart
sales@molnova.com
ACEPROMAZINE MALEATE
CAS No. 3598-37-6
ACEPROMAZINE MALEATE( —— )
Catalog No. M21050 CAS No. 3598-37-6
ACEPROMAZINE MALEATE is a dopamine receptor antagonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 42 | In Stock |
|
| 5MG | 38 | In Stock |
|
| 10MG | 61 | In Stock |
|
| 25MG | 88 | In Stock |
|
| 50MG | 110 | In Stock |
|
| 100MG | 166 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 408 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameACEPROMAZINE MALEATE
-
NoteResearch use only, not for human use.
-
Brief DescriptionACEPROMAZINE MALEATE is a dopamine receptor antagonist.
-
DescriptionACEPROMAZINE MALEATE is a dopamine receptor antagonist.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorDopamine
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3598-37-6
-
Formula Weight442.53
-
Molecular FormulaC23H26N2O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO:3mg/ml(6.8mM)
-
SMILESCC(=O)c1ccc2c(c1)N(CCCN(C)C)c1ccccc1S2.O=C(O)/C=C\C(=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Monteiro E R Neto F J T Castro V B et al. Effects of acepromazine on the cardiovascular actions of dopamine in anesthetized dogs[J]. Veterinary anaesthesia and analgesia 2007 34(5):312-321.
molnova catalog
related products
-
Alpha-Methyldopa Ses...
Alpha-Methyldopa Sesquihydrate is a DOPA decarboxylase inhibitor and indirect α2-adrenergic receptor agonist used to treat hypertension.?It inhibits the sympathetic nervous system decreases production of dopamine norepinephrine and epinephrine and exhibits NO-dependent sedative activity.
-
SB-277011
A potent and selective dopamine D3 receptor antagonist with pKi of 8.0.
-
Talquetamab
Talquetamab (JNJ-64407564) is a GPRC5D bispecific antibody for multiple myeloma (MM) that induces T-cell-mediated killing of GPRC5-expressing MM cells through T-cell recruitment and activation, demonstrating antitumor activity.
